Kerry Rogers, MD | Authors

Articles

Lead-In Treatment to Reduce Tumor Lysis Syndrome Risk in CLL

August 21, 2018

Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term treatment strategy for reducing tumor burden and the risk for tumor lysis syndrome in patients with chronic lymphocytic leukemia.

Exploring Early Ibrutinib Intervention in High-Risk CLL

December 10, 2017

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.